- Creates economic leverage with vertical integration of
database and management
EDINBURGH, Scotland, Nov. 2, 2023
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the
"Company") (NASDAQ: TCBP) a clinical stage biotechnology
company developing platform allogeneic gamma-delta T cell therapies
for cancer, announced today that it has selected of Fortrea
(FTRE) as the Company's Contract Research Organization (CRO) for
global trials, including ACHIEVE and ACHIEVE2.
The trials, in the UK and US respectively, will be managed by
Fortrea on an ongoing basis, creating a vertically integrated
clinical trial program which allows for increased operational
efficiencies, resulting in better data management and review
as well as value creation. TC BioPharm expects to generate cash
savings through the creation of these efficiencies by
consolidating CRO services under a single entity.
"Fortrea is a leading global CRO who we believe brings a wealth
of knowledge and experience that is expected to increase the
likelihood of success in both ACHIEVE and ACHIEVE2," said CEO
Bryan Kobel. "By consolidating these
trials under a single CRO we have established a unified database
for the trial management, removed potential miscommunication
issues, and eliminated an onerous cost structure, which we believe
will create cost savings. We appreciate Fortrea taking on
these exciting trials with us and look forward to data read outs in
2024."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-streamlined-efficiencies-and-reduces-overhead-with-selection-of-single-global-cro-for-clinical-trials-301976264.html
SOURCE TC BioPharm